Monday, December 23, 2024
HomeTagsCytoDyn

CytoDyn

Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst...

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported data from its trial treating...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics